MCC950 Alleviates Experimental Autoimmune Neuritis by Inhibiting NLRP3 Inflammasome Activity and Down-Regulating...

Area of Science:

• Neuroimmunology
• Inflammasome Biology

Background:

• Guillain-Barré syndrome (GBS) is a severe autoimmune neuropathy with unclear pathogenesis.
• The NLRP3 inflammasome and its role in neuroinflammation are increasingly recognized.

Purpose of the Study:

• To investigate the role of the NLRP3 inflammasome in regulating the IL-23/IL-17 axis in experimental autoimmune neuritis (EAN).
• To explore NLRP3 inflammasome as a potential therapeutic target for GBS.

Main Methods:

• Assessed NLRP3 inflammasome gene expression in GBS patient PBMCs via qPCR.
• Utilized MCC950, a NLRP3 inhibitor, in an EAN rat model.
• Evaluated sciatic nerve NLRP3 expression, protein levels of NLRP3 and IL-23/IL-17 axis, clinical symptoms, neurophysiology, and myelin integrity.

Main Results:

• Elevated NLRP3 inflammasome gene expression observed in GBS patients' peripheral blood.
• MCC950 treatment in EAN rats alleviated neurological symptoms, reduced immune cell infiltration, improved nerve conduction, and mitigated myelin loss.
• MCC950's protective effects were linked to inhibiting NLRP3 inflammasome signaling and downregulating the IL-23/IL-17 axis.

Conclusions:

• NLRP3 inflammasome activation contributes to EAN pathogenesis by upregulating the IL-23/IL-17 axis.
• These findings strongly support NLRP3 inflammasome as a viable drug target for GBS treatment.